Results 11 to 20 of about 9,702 (191)

Integration of circulating tumor DNA profiling in the risk stratification of classical Hodgkin lymphoma in children, adolescents, and young adults. [PDF]

Hemasphere
Abstract This study aimed to define the potential role of circulating tumor DNA (ctDNA) in children, adolescents, and young adults (CAYA) with classical Hodgkin lymphoma (cHL). This prospective trial was conducted in France between 2019 and 2023 and recruited CAYA patients (≤25 years old) with a new diagnosis of cHL.
Simonin M, Viennot M, Haouy S, Ducassou S, Curtillet C, Garnier N, Phulpin A, Paillard C, Rigaud C, Couec ML, Carausu L, Bonneau J, Pellier I, Barbati M, Millot F, Dourthe MÉ, Kanold J, Schneider P, Stephan JL, Leglise C, Pluchart C, Viailly PJ, Michel V, Boudjemaa S, Jonca B, Leblanc T, Landman-Parker J, Jardin F.   +27 more
europepmc   +2 more sources

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia. [PDF]

Am J Hematol
ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Ball S, Awan FT, Tomlinson BK, Stopczynski T, Fischer MA, Zhao Z, Fedorov K, Kishtagari A, Mohan SR, Ayers GD, Byrne MT, Savona MR.   +11 more
europepmc   +2 more sources

Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation

Cancer Medicine, 2023
Background XPO1 mediates the nuclear export of several proteins, mainly tumor suppressors. KPT‐330 (Selinexor) is a selective inhibitor of XPO1 that has demonstrated good therapeutic effects in hematologic cancers.
Cheng Zhao, Ben Ma, Zi‐yi Yang, Ou Li, Shi‐lei Liu, Li‐jia Pan, Wei Gong, Ping Dong, Yi‐jun Shu   +8 more
doaj   +1 more source

Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway

Journal of Translational Medicine, 2022
Background Gallbladder cancer (GBC) is a highly aggressive malignant cancer in the biliary system with poor prognosis. XPO1 (chromosome region maintenance 1 or CRM1) mediates the nuclear export of several proteins, mainly tumor suppressors.
Cheng Zhao, Zi-yi Yang, Jian Zhang, Ou Li, Shi-lei Liu, Chen Cai, Yi-jun Shu, Li-jia Pan, Wei Gong, Ping Dong   +9 more
doaj   +1 more source

Identification of Novel Covalent XPO1 Inhibitors Based on a Hybrid Virtual Screening Strategy

Molecules, 2022
Nuclear export protein 1 (XPO1), a member of the nuclear export protein-p (Karyopherin-P) superfamily, regulates the transport of “cargo” proteins.
Zheyuan Shen, Weihao Zhuang, Kang Li, Yu Guo, Bingxue Qu, Sikang Chen, Jian Gao, Jing Liu, Lei Xu, Xiaowu Dong, Jinxin Che, Qimeng Li   +11 more
doaj   +1 more source

The hippo kinase STK38 ensures functionality of XPO1 [PDF]

Cell Cycle, 2020
The proper segregation of basic elements such as the compartmentalization of the genome and the shuttling of macromolecules between the nucleus and the cytoplasm is a crucial mechanism for homeostasis maintenance in eukaryotic cells. XPO1 (Exportin 1) is the major nuclear export receptor and is required for the export of proteins and RNAs out of the ...
Alexandre PJ Martin, Jacques H Camonis
openaire   +2 more sources

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts

Translational Oncology, 2021
Gain-of-function Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations occur in 25% of lung adenocarcinomas, and these tumors are challenging to treat.
Joshua C. Rosen, Jessica Weiss, Nhu-An Pham, Quan Li, Sebastiao N. Martins-Filho, Yuhui Wang, Ming-Sound Tsao, Nadeem Moghal   +7 more
doaj   +1 more source

Circ-XPO1 upregulates XPO1 expression by sponging multiple miRNAs to facilitate osteosarcoma cell progression

Experimental and Molecular Pathology, 2020
Circular RNAs (circRNAs) act as a key role in mediating carcinogenesis. Nevertheless, the functions and mechanisms of circRNAs in osteosarcoma (OS) are still not fully understood. In the present study, we aim to investigate the functions of circ-XPO1 in OS and its potential mechanism underlying OS progression.
Yang, Jiang, Jiye, Hou, Xiaodong, Zhang, Guiqing, Xu, Yu, Wang, Lei, Shen, Yuxuan, Wu, Yongtao, Li, Lijie, Yao   +8 more
openaire   +2 more sources

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling

International Journal of Molecular Sciences, 2023
Acute myeloid leukemia (AML) is a high-mortality malignancy with poor outcomes. Azacitidine induces cell death and demonstrates treatment effectiveness against AML. Selinexor (KPT-330) exhibited significant benefits in combination with typical induction treatment for AML patients.
Huideng Long, Yue Hou, Jun Li, Chunhua Song, Zheng Ge   +4 more
openaire   +2 more sources

Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer [PDF]

, 2017
Background and aims: Docetaxel (DTX) modestly increases patient survival of metastatic castration-resistant prostate cancer (mCRPC) due to insurgence of pharmacological resistance. Deregulation of Chromosome Region Maintenance (CRM-1)/ exportin-1 (XPO-1)-
Argueta, Christian, BIORDI, ASSUNTA LEDA, Biordi, Leda Assunta, Colapietro, Alessandro, Festuccia, Claudio, Flati, Vincenzo, Gravina, Giovanni Luca, Iorio, Roberto, Kauffman, Michael, Landesman, Yosef, Mancini, Andrea, Marampon, Francesco, Pompili, Simona, Sferra, Roberta, Shacham, Sharon   +14 more
core   +2 more sources